Cargando…
Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme
BACKGROUND: Because multiple sclerosis (MS) is a chronic disease causing disability over decades, it is crucial to know if the short-term effects of disease-modifying therapies reported in randomised controlled trials reduce long-term disability. This 10-year prospective observational study of disab...
Autores principales: | Palace, Jacqueline, Duddy, Martin, Lawton, Michael, Bregenzer, Thomas, Zhu, Feng, Boggild, Mike, Piske, Benjamin, Robertson, Neil P, Oger, Joel, Tremlett, Helen, Tilling, Kate, Ben-Shlomo, Yoav, Lilford, Richard, Dobson, Charles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518464/ https://www.ncbi.nlm.nih.gov/pubmed/30242090 http://dx.doi.org/10.1136/jnnp-2018-318360 |
Ejemplares similares
-
Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score
por: Bsteh, Gabriel, et al.
Publicado: (2021) -
Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?
por: Cerqueira, João J, et al.
Publicado: (2018) -
MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis
por: Matthews, Lucy, et al.
Publicado: (2015) -
The contribution of neuropathology to multiple sclerosis research
por: Lassmann, Hans
Publicado: (2022) -
UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model
por: Palace, Jacqueline, et al.
Publicado: (2014)